
The higher drug forecasts accompany a 5% annual sales-growth outlook through 2031 as investors weigh the company’s prospects beyond that year.
Novartis raised its combined peak-sales forecast for three major drugs to $18 billion from $14 billion. The revised outlook covers multiple sclerosis drug Kesimpta, leukaemia treatment Scemblix and cholesterol medicine Leqvio.
CEO Vas Narasimhan said the upgrades reflect commercial performance, including market-share gains for Kesimpta and Scemblix and strong demand for Leqvio in the U.S. and Asia. “It's really that in-market commercial performance that's driving these upgrades,” he told reporters.
The company projected annual sales growth of 5% through 2031. That is slightly below its previous guidance of 5% to 6% through 2030, though the forecasts cover different periods.
Narasimhan said the revised outlook reflects expected U.S. generic competition for breast cancer treatment Kisqali in the second half of 2031. Citi analysts said the 2031 sales guidance was about 3% above consensus, but expected investors to remain cautious about growth beyond that year.
Novartis shares were down 2.53% as of 15:22 UTC on Thursday. Investors are weighing whether growth from the drugs can offset sales lost when older medicines face cheaper competition.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.